4.09 Problems with the VISION Trial & Stool Transplant Plus Nivo for Metastatic Melanoma

07.23.2021 - By Plenary Session

Download our free app to listen on your phone

Today we have two short monologues for you on recent papers. The first, by popular request, is the problems with the VISION trial, which treated metastatic castration-resistant prostate cancer with lutetium-177–PSMA-617 (Lu-177–PSMA-617) radioligand therapy and standard of care. The second is on the paper recently published in Science titled "Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients".

Fecal transplant: doi.org/10.1126/science.abb5920

Back us on Patreon! www.patreon.com/plenarysession

Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

More episodes from Plenary Session